ArticleNature communications2023
Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- The Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological, and Immunological Trajectory of COVID-19: Protocol for a Prospective Case-Ascertained and Surveillance Study.JMIR research protocols · 2026Article
- Impact of SARS-CoV-2 Breakthrough Infection on Short-Term CD4 Count Among Adults With HIV in the United States From 2020 to 2022.Open forum infectious diseases · 2026Article
- Single-Cell Transcriptomic Analysis of the Immune Response to COVID-19 and Tuberculosis Coinfection.Exploration (Beijing, China) · 2025Article
- Intensive Management of a Patient with HIV, Active Tuberculosis, and COVID-19: A Multidisciplinary Approach in the Intensive Care Unit.Life (Basel, Switzerland) · 2025Article
- Pathogen growth and virulence dynamics drive the host evolution against coinfections.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Individuals with latent tuberculosis in a high TB endemic country show mild COVID-19.PloS one · 2025Article
- COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa.PLOS global public health · 2025Article
- A Focus on the Mechanisms of Alteration in Host Lymphocyte Level Following Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Infection.Journal of inflammation research · 2025Review
- COVID-19 immune signatures in Uganda persist in HIV co-infection and diverge by pandemic phase.Nature communications · 2024Article
- Impact of Tuberculosis on Disease Severity and Viral Shedding Duration in COVID-19 Patients.Viruses · 2024Article
- Protective interplay:Frontiers in immunology · 2024Article
- Implementation of a genotyped African population cohort, with virtual follow-up: A feasibility study in the Western Cape Province, South Africa.Wellcome open research · 2024Article
- Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Genetic diversity, evolution and drug resistance ofFrontiers in microbiology · 2024Review
- T Cell Response in Tuberculosis-Infected Patients Vaccinated against COVID-19.Microorganisms · 2023Article
- COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa.Journal of the International AIDS Society · 2023Article
- Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis.Frontiers in immunology · 2023Review
- Immune interaction between SARS-CoV-2 andFrontiers in immunology · 2023Review
- Outbreaks of COVID-19 in a tuberculosis treatment sanatorium on the Thailand-Myanmar border: a retrospective cohort analysis.Wellcome open research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 3 countries.
Funding
Abstract
Few studies from Africa have described the clinical impact of co-infections on SARS-CoV-2 infection. Here, we investigate the presentation and outcome of SARS-CoV-2 infection in an African setting of high HIV-1 and tuberculosis prevalence by an observational case cohort of SARS-CoV-2 patients. A comparator group of non SARS-CoV-2 participants is included. The study includes 104 adults with SARS-CoV-2 infection of whom 29.8% are HIV-1 co-infected. Two or more co-morbidities are present in 57.7% of participants, including HIV-1 (30%) and active tuberculosis (14%). Amongst patients dually infected by tuberculosis and SARS-CoV-2, clinical features can be typical of either SARS-CoV-2 or tuberculosis: lymphopenia is exacerbated, and some markers of inflammation (D-dimer and ferritin) are further elevated (p < 0.05). Amongst HIV-1 co-infected participants those with low CD4 percentage strata exhibit reduced total, but not neutralising, anti-SARS-CoV-2 antibodies. SARS-CoV-2 specific CD8 T cell responses are present in 35.8% participants overall but undetectable in combined HIV-1 and tuberculosis. Death occurred in 30/104 (29%) of all COVID-19 patients and in 6/15 (40%) of patients with coincident SARS-CoV-2 and tuberculosis. This shows that in a high incidence setting, tuberculosis is a common co-morbidity in patients admitted to hospital with COVID-19. The immune response to SARS-CoV-2 is adversely affected by co-existent HIV-1 and tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.